The development of antitumor drugs targeting tryptophan metabolism has been primarily based on the tumor-promoting functions of IDO1 and TDO to develop small-molecule inhibitors of these enzymes for cancer treatments [31,32,33,34]. The gene discussed is TDO2; the disease is cancer.